Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers
- PMID: 28975930
- DOI: 10.1038/nrclinonc.2017.156
Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
